| __timestamp | CRISPR Therapeutics AG | Xenon Pharmaceuticals Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 5114000 | 5496000 |
| Thursday, January 1, 2015 | 13403000 | 9786000 |
| Friday, January 1, 2016 | 31056000 | 6792000 |
| Sunday, January 1, 2017 | 35845000 | 7313000 |
| Monday, January 1, 2018 | 48294000 | 8382000 |
| Tuesday, January 1, 2019 | 63488000 | 10803000 |
| Wednesday, January 1, 2020 | 88208000 | 12944000 |
| Friday, January 1, 2021 | 102802000 | 21967000 |
| Saturday, January 1, 2022 | 102464000 | 32810000 |
| Sunday, January 1, 2023 | 76162000 | 46542000 |
| Monday, January 1, 2024 | 72977000 |
Infusing magic into the data realm
In the competitive world of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for sustaining growth and innovation. CRISPR Therapeutics AG and Xenon Pharmaceuticals Inc. have been at the forefront of this challenge since 2014. Over the past decade, CRISPR Therapeutics AG has seen its SG&A expenses grow by approximately 1,400%, peaking in 2021. In contrast, Xenon Pharmaceuticals Inc. has maintained a more conservative growth of around 750% in the same period.
By 2023, CRISPR's SG&A expenses were about 63% higher than Xenon's, reflecting its aggressive expansion strategy. However, Xenon’s steady increase suggests a more controlled approach, potentially offering better cost optimization. As these companies continue to innovate, their ability to manage these costs will be pivotal in determining their long-term success.
Cost Management Insights: SG&A Expenses for Teva Pharmaceutical Industries Limited and CRISPR Therapeutics AG
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Xenon Pharmaceuticals Inc.
Who Optimizes SG&A Costs Better? Viatris Inc. or CRISPR Therapeutics AG
Who Optimizes SG&A Costs Better? Insmed Incorporated or Xenon Pharmaceuticals Inc.
Operational Costs Compared: SG&A Analysis of Opthea Limited and CRISPR Therapeutics AG
Axsome Therapeutics, Inc. and Xenon Pharmaceuticals Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Xenon Pharmaceuticals Inc.
Selling, General, and Administrative Costs: Amneal Pharmaceuticals, Inc. vs Xenon Pharmaceuticals Inc.
CRISPR Therapeutics AG and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
CRISPR Therapeutics AG or HUTCHMED (China) Limited: Who Manages SG&A Costs Better?
CRISPR Therapeutics AG or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of CRISPR Therapeutics AG and Viridian Therapeutics, Inc.